Sartorius Stedim Biotech (DIM) Q2 2024 earnings summary

Executive summary

• H1 2024 results met guidance, with sales revenue at €1.68 billion (down 2.2% in constant currencies), and Q2 showing sequential growth; bioprocess sales held steady while lab division and China remained weak.

• Underlying EBITDA margin was robust at 28.2%–28.1%, though net profit and EPS fell sharply year-over-year; efficiency and cost programs partially offset lower volumes.

• Order intake increased by 8.5%–11.2% in constant currencies, driven by recurring business and some demand normalization.

• Market fundamentals remain intact, but post-pandemic normalization is incomplete, with ongoing inventory reductions, low visibility, and persistent volatility.

• Workforce reduced to 10,382, mainly through attrition and expiry of fixed-term contracts.

Financial highlights

• H1 2024 sales: €1.68 billion (down 2.2% in constant currencies); underlying EBITDA: €471 million (down 8.8%); underlying EBITDA margin: 28.2%–28.1%.

• Free cash flow rose to €108 million, mainly due to reduced CapEx; CapEx as a percentage of sales decreased to 13.6%.

• Net debt reduced to €2,465 million–€4,033 million; net debt/EBITDA improved to 3.3–4.4x.

• Underlying net profit dropped to €104 million–€165 million; underlying EPS was €1.71.

• Equity ratio increased to 38.3%–48.6% due to capital increase.

Outlook and guidance

• FY 2024 guidance de-risked: sales expected flat year-over-year, with a range from low single-digit negative to low single-digit positive growth.

• Polyplus acquisition to contribute about 2 percentage points to group sales.

• Underlying EBITDA margin forecast revised to 27–29% (previously above 30%).

• CapEx-to-sales ratio expected around 12%; net debt/EBITDA targeted at 2.5–4.0 by year-end.

• No change to medium-term targets up to 2028.